7 April 2016Americas

DLA Piper adds partner and chair of FDA group

Law firm DLA Piper has hired James Czaban as a partner in the firm’s government affairs practice and chair of the firm’s US Food and Drug Administration group in Washington, DC.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

article

Why you shouldn’t overlook Canadian IP litigation

2 October 2017 Canada has a robust and reliable framework for resolving IP disputes, and it shouldn’t be ignored by litigants, say Ron Dimock, Sangeetha Punniyamoorthy and Nikolas Purcell of DLA Piper.

DLA Piper recruits life sciences lawyer for Silicon Valley

29 July 2014 DLA Piper has appointed life sciences lawyer Shane Albright to its corporate and finance practice.

FDA clears orphan drug backlog

14 September 2017 The Food and Drugs Administration has cleared the backlog of orphan drug designation requests, one month early.

More on this story

DLA Piper recruits life sciences lawyer for Silicon Valley

29 July 2014 DLA Piper has appointed life sciences lawyer Shane Albright to its corporate and finance practice.

FDA clears orphan drug backlog

14 September 2017 The Food and Drugs Administration has cleared the backlog of orphan drug designation requests, one month early.

article

Why you shouldn’t overlook Canadian IP litigation

2 October 2017 Canada has a robust and reliable framework for resolving IP disputes, and it shouldn’t be ignored by litigants, say Ron Dimock, Sangeetha Punniyamoorthy and Nikolas Purcell of DLA Piper.

More on this story

DLA Piper recruits life sciences lawyer for Silicon Valley

29 July 2014 DLA Piper has appointed life sciences lawyer Shane Albright to its corporate and finance practice.

FDA clears orphan drug backlog

14 September 2017 The Food and Drugs Administration has cleared the backlog of orphan drug designation requests, one month early.

article

Why you shouldn’t overlook Canadian IP litigation

2 October 2017 Canada has a robust and reliable framework for resolving IP disputes, and it shouldn’t be ignored by litigants, say Ron Dimock, Sangeetha Punniyamoorthy and Nikolas Purcell of DLA Piper.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent